Century Therapeutics (IPSC) Stock Analysis & Winston Score

Century Therapeutics is a biotechnology company working on cancer treatments. Instead of using a patient's own cells, it engineers stem cells in a lab to create "off-the-shelf" immune cell therapies — mainly CAR-T and CAR-NK cells — that can be made in advance and given to any patient. Its main customers are cancer patients, and it works closely with larger pharmaceutical partners, including Bristol-Myers Squibb. The company does not yet sell any approved products, so it earns revenue primarily through collaboration agreements and research partnerships rather than product sales. It operates mainly in the United States and had a market cap of roughly $200 million as of mid-2026, reflecting its early-stage status. The key growth driver is advancing its pipeline candidates through clinical trials toward regulatory approval, but the main risk is that it continues burning cash with no guarantee any therapy will reach the market — a common and serious challenge for pre-revenue biotech companies.